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Abstract 
To understand the role of calbindin-D 28K in neuronal degeneration, we examined its expression in differentiated PC12 cells in response to calcium 
intoxication, using the ionophore A231 87 treatment, hat results in cell degeneration and death. We first established that calbindin-D 28K is expressed 
in PC12 cells. The amounts of calbindin-D 28K mRNA and protein were increased by the differentiation factors, NGF and retinoic acid, but not 
by vitamin D3. Calbindin-D 28K expression was also significantly up-regulated by stimuli (depolarization, low concentrations of Ca” ionophore 
A23187) which increase intracellular calcium levels within the physiological range. In contrast, the calbindin-D 28K mRNA and protein concentra- 
tions were not modulated by high concentrations of A23187, which resulted in cell degeneration and death. Experiments with the antisense 
oligonucleotides howed that, although the calbindin-D 28K protein levels were decreased significantly, the progression of degenerative changes 
induced by calcium via A23187, was not altered. 
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1. Introduction 
The calcium binding protein (CaBP), calbindin-D 28K 
is widely but heterogeneously distributed in the brain 
[1,2]. This protein belongs to a family of CaBPs that is 
characterized by a common structural calcium binding 
domain designated as the E-F hand [3,4]. In calbindin-D 
28K, four such domains are present [5,6], including a 
unique site to which calcium binds with a very high 
affinity [7], suggesting that it plays an important role in 
the maintenance of calcium homeostasis. The evidence 
that it regulates intracellular calcium by sequestering ex- 
cess Ca” is partly indirect and includes: its cytoplasmic 
localization; its high abundance in specific brain regions, 
for example, hippocampus, caudate putamen, and cere- 
bellum; its co-localization with inositol triphosphate re- 
ceptors which are involved in the release of Ca” from 
intracellular stores and its increased expression in hip- 
pocampal neurons following electrical stimulation [8- 
lo]. Other roles for calbindin-D 28K have also been 
suggested including modulation of the functions of Ca2’- 
dependent proteins such as voltage-gated calcium chan- 
nels [ll]. 
Calbindin-D 28K is believed to protect cells against 
increases in intracellular Ca2’ that in time, could spread 
and damage the neuron and subsequently threaten its 
viability. This may also explain the selective vulnerability 
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to pathological processes in neurons lacking this protein 
compared to those containing it. Several studies have 
shown a reduction in the expression of calbindin-D 28K 
specifically in the neurons most affected in neurodegen- 
erative diseases, for example, Alzheimer, Huntington 
and Parkinsons’ disease (PD) [12-141. In Parkinsonian 
patients and in the experimental animal model of PD, the 
MPTP (1 -methyl-4-phenyl- 1,2,3,6_tetrahydropyridine)- 
treated mice, the dopaminergic neurons of substantia 
nigra pars compacta that have not degenerated are im- 
munopositive for calbindin-D 28K [15-l 81, reinforcing 
the idea that this protein has a neuroprotective function. 
To understand the role of calbindin-D 28K during 
cellular degeneration, we studied the expression of its 
mRNA and protein in differentiated PC12 cells exposed 
to low and high concentrations of calcium ionophore 
A23187. 
2. Materials and methods 
2.1. PC12 cell culture and treatment procedures 
PC12 cells were cultivated in RPM1 1640 medium (G&co, BRL) 
supplemented with 10% fetal calf serum (FCS), 5% horse serum (HS) 
(Boehringer) and antibiotics (100 &ml streptomycin and 60 &ml 
penicillin). They were differentiated in a modified Leibovitz’s L15 me- 
dium containing 5% FCS, 10% HS, and 50 rig/ml 2.5s NGF (Boehrin- 
ger) 1191. The cells were allowed to differentiate for 7 davs and the - __ 
culture medium was changed every 2-3 days. For Northern and West- 
ern blot analysis, the cells were grown to about 80% confluency in 
culture dishes and then treated with the calcium ionophore A23187 
(Boehringer), veratridine (Sigma) or maintained in 50 mM KC1 medium 
in which case an equivalent amount of NaCl was omitted from the 
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medium. Cells for retinoic acid treatment were grown in RPM1 1640 
medium for 5-7 days. 
2.2. Immunocytochemistry 
Cells were immunolabelled for calbindin-D 28K as described previ- 
ously [20]. Monoclonal anti-calbindin-D 28K antibody (Sigma) was 
diluted l/250 in phosphate-buffered saline (PBS) and the secondary 
antibody was mouse anti-IgG. Incubation with avidin-biotinylated 
horseradish peroxidase complex (Vectastain Kit, Vector Lab, Burling- 
ame, USA) was followed by treatment with diaminobenzidine xposure 
to reveal immunolabelling. The specificity of the antibody had been 
ascertained by preadsorption assay with commercially (Sigma) ob- 
tained calbindin-D 28K protein. 
2.3. Northern blot analysis 
Total RNA was prepared by the method of Chomczynski and Sacchi 
[21]. 8 lg total RNA was electrophoresed in 1% agarose-formaldehyde 
gel and transferred to Hybond N’ membranes (Amersham). The cal- 
bindin-D 28K cRNA probe [22] was prepared by first linearizing the 
plasmid with EcoRI enzyme and then synthetized using an in vitro 
transcription kit (Promega), radioactively labelling with [“PIUTP. The 
blots were hybridized with the probe at 50°C for 1624 h, washed under 
stringent conditions and autoradiographed. 
2.4. Western blot analysis 
Total cell protein was extracted in ice-cold RIPA buffer containing 
PBS, 1% NP40, 0.5% Na deoxycholate, 0.1% SDS, 100 &ml PMSF, 
5 &ml aprotonin. The cells were disrupted by brief sonication, incu- 
bated on ice for 30 min and centrifuged in the microfuge for 30 min at 
4°C. The amount of protein in the supematant was measured by the 
method of Bradford [23]. 15 ,ug was electrophoresed on 9% PAGE and 
transferred to Immobilon P (Millipore) membranes. The blots were 
incubated with anti-calbindin-D 28K antibody (11250) and processed 
for immunodetection by treatment with a secondary anti-mouse IgG 
antibody conjugated to horseradish peroxidase, and the signal detected 
using the ECL detection kit (Amersham). 
2.5. Treatment with antisense oiigonucleotides 
Three antisense (or sense as controls) phosphorothioate-modified 
oligonucleotides, (Genset, Paris) each 20-21 bp long, were synthesized. 
The cells were incubated with a mixture of either 3 antisense or 3 sense 
oligonucleotides, each at a final concentration of24,uM, in a serum-free 
modified L- 15 medium but in the presence of NGF. Serum-free condi- 
tions were used because short-length oligonucleotides have been re- 
ported to degrade rapidly in the presence of serum proteins [24]. The 
cells were treated with the oligonucleotides every 24 h for 48 h, period 
during which the differentiation process and cell viability remained 
unaffected. 
The cDNA sequences of oligonucleotides were as follows: 
(a) 5’-GCAGAATCCCACCTGCAGTCA-3 
(b) 5’-TCTGGCTTCATTTCGACGGT-3 
(c) 5’-AACAAGACCGTGGATGATACG-3 
2.6. Quantification 
mRNA and protein signals were quantified by optical densitometry 
using a Biocom image analysis system (Les Ulis, France). 
3. Results 
Almost all the NGF-differentiated PC12 cells con- 
tained immunolabelled calbindin-D 28K in the cyto- 
plasm and in the neurite processes (Fig. 1). NGF-in- 
duced differentiation of PC12 cells (50 &ml, 5 days) 
resulted in a two-fold increase in both the mRNA and 
protein levels (Fig. 2A,B). To discern whether calbindin- 
D 28K synthesis increased as a result of neuronal differ- 
entiation induced by NGF, or if other differentiating 
factors modulate its expression, the cells were treated 
Fig. 1. Differentiated PC12 cells immunolabelled with anti-calbindin-D 
28K antibody. Bar = 10 pm. 
with retinoic acid or vitamin D3. While 10 ,uM retinoic 
acid treatment did not result in morphological differenti- 
ation of PC12 cells, it nevertheless caused a 3-fold in- 
crease in the calbindin-D 28K mRNA levels (Fig. 2A). 
The increase in protein amount was similar to NGF at 
10 ,uM retinoic acid, but a further augmentation was 
observed at 20 ,uM of retinoic acid (Fig. 2B). The cal- 
bindin-D 28K mRNA remained unchanged after vitamin 
D, (500 nM) treatment (data not shown). 
The calbindin-D 28K mRNA levels were measured in 
NGF-differentiated PC12 cells treated with increasing 
concentrations of A23187 for 24 h. Most noticeably, at 
10 and 50,uM of A23187, there was a 50 and 90-95% loss 
in cell viability, respectively (Fig. 3A), whereas the lower 
concentrations did not affect the cell survival signifi- 
cantly. The calbindin-D 28K mRNA levels in cells 
treated with low concentrations (0.1 and 1 yM) of 
A23 187 increased by 3- and 4-fold, respectively (Fig. 3B), 
before any morphological changes or cell death oc- 
curred. Concentrations of A23187 above 1 ,uM A23 187 
caused a dose dependent drop in calbindin-D 28K 
mRNA; there was significantly smaller increase at 3 ,uM 
although the level was still above control. At this concen- 
tration, after 24 h of incubation, extensive neurite frag- 
mentation was observed but cell survival was not com- 
promised (data not shown). The calbindin-D 28K 
mRNA level at 10 PM A231 87 was similar to control in 
the surviving PC12 cells, and had dropped below control 
at 50 ,uM (Fig. 3B). We monitored calbindin-D 28K 
protein levels in cells treated with 10 ,uM A23187 over 
a period ranging from 2 to 36 h in order to see whether 
the calbindin-D 28K levels were augmented prior to cell 
degeneration and death. There was no change in protein 
level (Fig. 3C) at all times tested although degeneration 
was ongoing, and cell death was observed after 12 h. 
The above results showing that calbindin-D 28K ex- 
pression is modulated only at low concentrations of 
A231 87 led us to examine the effect of other stimuli 
which result in increased intracellular Ca*‘. The NGF- 
differentiated PC12 cells were treated with a depolarizing 
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Fig. 2. PC12 cells incubated with NGF (50 nglml) and retinoic acid (10 
,uM) for 5 days. (A) Calbindin-D 28K mRNA levels of control and 
treated cells, the major transcript size in these cells was 2.8 kb. The 
mRNA sizes were verified with RNA markers and by rehybridization 
of the membranes with the/Lactin cDNA probe, (mRNA: 1.9 kb). (B) 
Protein levels were measured by Western blot analysis, the molecular 
weight (28 kDa) was verified by protein standards. The cells were 
treated with NGF and with either 10 or 20 PM retinoic acid (RA) for 
5 days. The quantified mRNA and protein levels are presented in 
arbitrary units. 
concentration of K’ (50 mM), or with veratridine (10 
PM) for 2 and 24 h. These concentrations, known to 
increase Ca2’ influx, did not induce degenerative 
changes. Depolarization by K’ induced a IO-fold in- 
crease in calbindin-D 28K mRNA level which was max- 
imal at 2 h; veratridine produced a smaller but noticeable 
(Zfold) increase on calbindin-D 28K mRNA. For com- 
parison, incubation with 1 ,uM A23 187 resulted in B-fold 
increase in calbindin-D 28K mRNA at 2 h which in- 
creased to a slightly higher level at 24 h (Fig. 4A). The 
rise in calbindin-D 28K protein levels paralleled in time 
the changes in mRNA levels (Fig. 4B), and were all of 
a similar magnitude. 
To determine whether the calbindin-D 28K had a pro- 
tective function during calcium-induced egeneration in- 
duced by calcium ionophore, the differentiated PC12 
cells were treated with a mixture of three modified 
phosphothiorate antisense oligonucleotides in a serum- 
free medium containing NGF. Untreated cells were more 
susceptible to A23187 toxicity in the absence of serum 
proteins; the dose-response curve of ionophore toxicity 
was shifted toward lower concentrations. At A23187 
concentrations of l-2 PM cell degeneration began after 
3-4 h of treatment. Cells incubated with 1.5 PM A23187 
alone (control), or with sense or antisense oligonucleo- 
tides showed no significant difference in the progression 
of morphological degenerative changes. However, the 
calbindin-D 28K protein concentration in antisense- 
treated cultures was decreased by 50-60%, (Fig. 5), 
whereas in the sense oligonucleotide-treated cultures, the 
decrease in the protein level was l&15% (data not 
shown). 
4. Discussion 
We show that both NGF and retinoic acid, well char- 
acterized differentiation factors, stimulate the expression 
of the calbindin-D 28K. These factors have opposing 
neurochemical and morphological actions in PC12 cells. 
Whereas NGF causes PC12 cells to differentiate into 
sympathetic neuron-like cells and promotes catecholam- 
inergic traits [26], retinoic acid has no effect on their 
morphology but induces a cholinergic neurochemical 
phenotype [24]. The function of calbindin-D 28K in neu- 
ronal development and differentiation has been evoked 
in ontogenic studies [27] and it is induced during develop- 
ment by target-derived and trophic factors [28-311. 
Treatment of NGF-differentiated PC12 cells with low 
concentrations of A23187 or depolarizing agents which 
elicit physiologically relevant rises in intracellular Ca*+, 
and were non-toxic for these cells, resulted in a rapid and 
prolonged up-regulation of calbindin-D 28K mRNA and 
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Fig. 3. Treatment of differentiated PC12 cells with increasing concen- 
trations of A23187. (A) Cell viability was measured by Trypan blue 
exclusion. The results are expressed as % of cells excluding dye after 24 
h of A23187 treatment. (B) Northern blot analysis of calbindin-D 28K 
mRNA after A23187 treatment for 24 h. The quantitied results ex- 
pressed in arbitrary units as the means of three experiments. (C) Differ- 
entiated PC1 2 cells were treated with 10 PM A23 187 for varying times 
and the calbindin-D 28K protein concentrations measured. 
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protein levels. The low (1 yM) concentration of A23187 
used in this study has been shown to elevate basal intra- 
cellular Ca” by 5-lo-fold [32], a range comparable to 
depolarization [I I]. The results strongly suggest that 
Ca2’ itself may play a role in maintaining its own home- 
ostasis in physiological situations by regulating the ex- 
pression of calbindin-D 28K gene. This result is also in 
keeping with the study of Lowenstein et al. [IO] showing 
the induction of calbindin-D 28K mRNA in the granule 
cells of the hipppocampus in vivo following neuronal 
stimulation that increases intracellular Ca2’. In differen- 
tiated PC1 2 cells, this compensatory phenomenon could 
be an efficient way of safeguarding the cell morphology. 
In contrast, calbindin-D 28K gene transcripts fell to con- 
trol levels at A23187 concentrations that resulted in cel- 
lular degeneration, and as well, the protein levels re- 
mained constant at 10 PM A23 187 during both the early 
non-degenerative period and in the degenerative period. 
Although there was no up-regulation, the calbindin-D 
28K protein levels were not significantly diminished in 
cells undergoing degeneration suggesting that even 
though the calcium regulatory processes may be func- 
tional they are not sufficient to prevent cell death. As 
regards to regulation of calbindin-D 28K gene expres- 
sion, the results suggest that above a threshold concen- 
tration of cytosolic Ca2+, the calbindin-D 28K gene ex- 
pression is not modulated nor is it regulated by any 
molecular changes occurring during calcium-induced de- 
generation. In agreement with this finding, Iacopino et 
al. [33] also reported that the amount of calbindin-D 28K 
expression remained unchanged in the degenerating and 
dying neurons of mice treated with MPTP, kainic acid 
or quinolic acid. When the calbindin-D 28K concentra- 
tions were decreased by incubating the cells with anti- 
A 
abobob 
ababob abobob 
mRNA protein 
Fig. 4. Treatment of differentiated PC12 cells with veratridine (IO,UM), 
high K’ (50 mM), and 1 ,uM A231 87 for 2 h (a) and 24 h (b). The mRNA 
(A) and protein (B) signals were quantified and are expressed in arbi- 
trary units (C). 
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Fig. 5. Treatment of differentiated PC12 cells with antisense oligonucle- 
otides for 48 h in serum-free medium containing NGF. (A) Measure- 
ment and quantification ofcalbindin-D 28K protein in oligonucleotide- 
treated (AS) and untreated cells. (B) The cells were incubated in the 
absence of serum and treated with I .5 ,uM A23187 (lono) for 24 h with 
or without antisense oligonucleotides. Cell survival was measured by 
Trypan blue exclusion. Results are expressed as % of corresponding 
controls. 
sense oligonucleotides, this had no effect on the progres- 
sion of cell degeneration induced by A23 187, suggesting 
that calbindin-D 28K makes no important contribution 
to the paradigm of A23187-induced toxicity. 
These in vitro results suggest that in response to phys- 
iological increase in intracellular Ca’+, the calbindin-D 
28K positive neurons in the brain are able to regulate 
calcium levels aided by up-regulation of calbindin-D 
28K, which thus protects these neurons in a continual 
manner, Above certain Ca2’ concentration, the compen- 
satory calbindin-D 28K regulating mechanism becomes 
nonfunctional contributing to pathway of cell death. 
Neurons which contain little or no calbindin-D 28K are 
more susceptible to pathological processes as are the 
neurons of hippocampus during aging and in hypoxia- 
ischemia [34,35] or the mesencephalic dopaminergic neu- 
rons that degenerate in Parkinson’s disease [ 17,181. How- 
ever, calbindin-D 28K is only one of the CaBPs in the 
brain; parvalbumin and calretinin are also implicated in 
Ca2’ homeostasis [8]. Increased intracellular calcium is 
suggested to be a final mediator of cell death [ 15,361 and 
augmented calbindin-D 28K mRNA and protein expres- 
sion could contribute in prolonging the survival of de- 
generating neurons. But this remains hypothetical as the 
direct causes of cell death in neurodegenerative disorders 
and aging remain to be elucidated. 
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